Reply:

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/86969/1/24520_ftp.pd

Hepatitis B Treatment: What We Know Now and What Remains to Be Researched

Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/147072/1/hep41281.pdfhttps://deepblue.lib.umich.edu/bitstream/2027.42/147072/2/hep41281_am.pd

Progress in hepatitis B: A 30‐year journey through three continents

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/107540/1/hep27120.pd

Endpoints of hepatitis B treatment

The goal of hepatitis B treatment is to prevent the development of cirrhosis, liver failure, and hepatocellular carcinoma. Ideally, clinical studies should demonstrate that hepatitis B therapies can prevent liver-related complications; however, these clinical endpoints evolve over years or decades. Therefore, clinical trials have relied on intermediate endpoints to evaluate the efficacy of treatment and to determine when treatment can be stopped. Intermediate endpoints that have been used include biochemical, histological, virological, and serological endpoints. This review will discuss the validity of these intermediate endpoints as surrogates of clinical endpoints, and the rates at which these intermediate endpoints can be achieved with currently available therapies.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/79271/1/j.1365-2893.2010.01369.x.pd

Prevention of recurrent hepatitis B post–liver transplantation

1 Factors associated with a lower rate of recurrent hepatitis B post–liver transplantation (LT) are negative hepatitis B e antigen and/or serum hepatitis B virus DNA pre-LT, hepatitis D virus superinfection, and fulminant hepatitis B. 2 Long-term intravenous hepatitis B immune globulin (HBIG) monotherapy can reduce the overall rate of recurrent hepatitis B to 20% to 35%. 3 Long-term lamivudine monotherapy is associated with a risk for drug resistance and overall 3-year rate of recurrent hepatitis B of 40% to 50%. 4 Combination prophylaxis with HBIG and lamivudine can reduce the overall rate of recurrent hepatitis B to 0% to 10%. 5 The dose and duration of HBIG therapy needed when used in combination with lamivudine may be lower, but the optimal regimen remains to be determined. 6 Lamivudine resistance before LT is associated with an increased risk for recurrent hepatitis B post-LT. 7 A cost-effective prophylactic regimen to prevent recurrent hepatitis B should be tailored according to risk.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/35278/1/500081013_ftp.pd

Reply:

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/87032/1/24410_ftp.pd

World-wide epidemiology of HBeAg-negative chronic hepatitis B and associated precore and core promoter variants

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/72281/1/j.1365-2893.2002.00304.x.pd

Identification and Management of Hepatitis C Patients in Primary Care Clinics

Previous survey-based research suggested that hepatitis C patients receive suboptimal care in primary care settings. The aim of our study was to define the actual level of care hepatitis C patients receive in primary care clinics. Methods Medical records of 229 hepatitis C antibody-positive (group 1), 229 hepatitis C antibody-negative (group 2), and 229 patients not tested for hepatitis C antibody (group 3) were reviewed to assess the indications for hepatitis C testing and the subsequent management and referral of hepatitis C antibody-positive patients diagnosed in primary care clinics. In addition, the compliance of primary care physicians with hepatitis C screening and testing guidelines was assessed. Results Only 16 of group 1 and 10 of group 2 patients were tested for hepatitis C based on physician-identified risk factors. Only 1 of group 3 patients had documented discussion of hepatitis C risk factors during their initial visit with a primary care physician. The majority of hepatitis C antibody-positive patients was appropriately evaluated in primary care clinics, and most (77 ) hepatitis C RNA-positive patients with elevated liver enzymes were referred for subspecialty care. Of the 59 patients who underwent liver biopsy, 40 had bridging fibrosis or cirrhosis. Conclusions Hepatitis C testing is rarely initiated in primary care clinics based on physician-identified risk factors. Interventions should be developed to optimize early diagnosis of hepatitis C as significant liver disease may be present despite the absence of symptoms.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/75608/1/j.1572-0241.2003.07331.x.pd

Chronic hepatitis B

No Abstract.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/34785/1/510340622_ftp.pd

Reply

No Abstract.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/34793/1/510370333_ftp.pd